Wellington Management Group LLP Bio Atla, Inc. Transaction History

Wellington Management Group LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$2.3 - $8.25 $840,024 - $3.01 Million	365,228 New	365,228 $978,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $1.89 Million - $4.78 Million	-887,929 Reduced 96.64%	30,915 $88,000
Q1 2022 May 16, 2022	SELL	$4.38 - $18.78 $10.1 Million - $43.5 Million	-2,313,636 Reduced 71.57%	918,844 $4.6 Million
Q4 2021 Feb 11, 2022	BUY	$19.0 - $30.95 $17.9 Million - $29.1 Million	940,543 Added 41.04%	3,232,480 $63.5 Million
Q3 2021 Nov 15, 2021	SELL	$29.44 - $43.74 $2.33 Million - $3.47 Million	-79,310 Reduced 3.34%	2,291,937 $67.5 Million
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $32.6 Million - $48.2 Million	857,586 Added 56.66%	2,371,247 $100 Million
Q1 2021 May 17, 2021	BUY	$32.41 - $70.91 $29.7 Million - $65 Million	916,905 Added 153.65%	1,513,661 $77 Million
Q4 2020 Feb 12, 2021	BUY	$31.02 - $35.16 $18.5 Million - $21 Million	596,756 New	596,756 $20.3 Million

23.4M

30.8K

57K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $12M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.